On May 21, 2019, MAPS submitted a new study protocol to the U.S. Food and Drug Administration (FDA) for a Phase 1 open-label, multi-site research study of the safety and psychological effects of manualized MDMA-assisted psychotherapy in healthy volunteer therapists (Study MT2), similar in design to the previous study in healthy volunteer therapists, Study MT1, which was not placed on clinical hold by FDA.